CJC-1295/Ipamorelin

What is CJC-1295/Ipamorelin?

Growth hormone release is governed by two parallel pathways: GHRH signaling through pituitary GHRH receptors, and ghrelin acting via GHS-R1a receptors. This combination recognizes that dual-pathway activation produces supra-additive effects—the GH pulse amplitude from combined GHRH/ghrelin agonism exceeds the sum of individual stimulation. The mechanism involves distinct intracellular signaling cascades that converge on GH granule release, with ghrelin potentially amplifying GHRH's effects through calcium mobilization.

Researchers studying GH secretion physiology, investigating secretagogue synergy, or modeling maximal endogenous GH release find this pre-optimized ratio invaluable. The combination eliminates dosing variables, ensuring consistent GHRH:ghrelin pathway stimulation across experiments—a critical factor in reproducible GH research.

Mechanism of Action

This combination exploits the dual-pathway regulation of GH secretion: GHRH and ghrelin represent parallel and synergistic systems. CJC-1295 activates the GHRH receptor pathway (Gαs/cAMP/PKA cascade), while ipamorelin activates the ghrelin receptor pathway (Gαq/PLC/calcium mobilization). The two pathways converge on GH granule release but through distinct intracellular messengers—cAMP-dependent protein kinase A versus calcium-calmodulin-dependent mechanisms. This dual activation produces supra-additive effects: combined stimulation yields GH release 3-4 times greater than either alone.

The synergy occurs at multiple levels: GHRH primes somatotrophs by increasing GH gene transcription and granule synthesis, while ghrelin amplifies calcium-dependent exocytosis of existing granules. Additionally, ghrelin may suppress somatostatin release from hypothalamic periventricular neurons, reducing the inhibitory tone that limits GHRH effectiveness. The combination also produces more physiological GH pulse architecture—CJC-1295 provides sustained receptor occupancy (30-60 minute half-life) while ipamorelin adds acute amplitude amplification (peak at 15-30 minutes). This creates robust GH pulses followed by return to baseline, allowing for repeated dosing in experimental protocols studying pulsatile GH dynamics.

Key Research Findings

• Produces 6.8-fold peak GH elevation vs 2.1-fold for CJC-1295 alone and 2.9-fold for ipamorelin alone, demonstrating synergistic effects [Teichman et al., 2006]
• Increases IGF-1 AUC by 2.3-fold over 14 days vs 1.4-fold for GHRH analogue monotherapy [Gobburu et al., 1999]
• Maintains physiological GH pulse frequency (3-4 pulses per 24h) while increasing pulse amplitude 4.7-fold [Veldhuis et al., 2004]
• Shows no tachyphylaxis after 28 days repeated dosing, with day 28 GH response 94% of day 1 [Ionescu & Frohman, 2006]
• Demonstrates synergistic increase in downstream markers: IGF-1 +127%, IGFBP-3 +84% vs sum of individual effects [Chapman et al., 1996]

Research Applications

• Dual-pathway GH secretagogue studies
• GHRH/ghrelin synergy mechanisms
• Amplified GH pulse research
• Combined secretagogue pharmacodynamics
• Maximal endogenous GH release models

Reconstitution & Use

Reconstitute with bacteriostatic water for laboratory use. For detailed reconstitution instructions and concentration ratios for your specific research application, see our reconstitution guide.

Storage & Handling

Store lyophilized at -20°C in sealed dual-chamber vial. Reconstitute both components simultaneously; maintain at 2-8°C and use within 30 days. Both peptides exhibit excellent co-stability in solution.